Pioneering Macrophage Cell Therapy for Transformative Outcomes in Inflammatory Organ Diseases

Inflammatory organ disease affects millions of patients worldwide. We aim to treat these patients, for example by helping patients with liver cirrhosis avoiding the need for a transplantation.

The Science +

Harnessing the healing power of the macrophage

Resolution Therapeutics is developing macrophage cell therapies to treat diseases characterised by life-threatening inflammatory organ damage. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, manufacture and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes.

Latest News

01/07/2024

Resolution Therapeutics R&D Webinar

Watch as Resolution's CEO Amir Hefni PhD. and CMO Dr. Cliff Brass are joined by liver cirrhosis patient advocate Steven Rodrigues, and world leading hepatologist Dr. Arun Sanyal for Resolution's first R&D webinar, hosted live on Friday 28th June 2024 at 12.30 BST.

READ MORE +
27/06/2024

Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001

Edinburgh and London, UK, 27 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease today announces it has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase I/II EMERALD study for its lead candidate RTX001.

READ MORE +
13/06/2024

Resolution Therapeutics to Host Virtual R&D Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.

Highlighting Clinical Data and Discovery Platform Following Presentations at EASL Congress 2024 Edinburgh and London, UK, 13 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease, today announces that it will host a virtual R&D webinar on Friday 28th June 2024 at 12.30 BST / 7.30 EDT for investors, analysts and media.

READ MORE +
12/06/2024

Meeting the Challenge of Manufacturing Macrophages

Working with macrophages, Resolution Therapeutics faces a “unique” manufacturing challenge. They progressively lose cells as they move towards their final product. Damian Marshall, PhD, VP, analytics, and Steve Howe, PhD, VP, process development, talk to GEN about how they’re tackling the move towards commercialization.

READ MORE +
05/06/2024

Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024

Edinburgh and London, UK, 5 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease today announces key data presentations with the University of Edinburgh at the EASL Congress 2024, held in Milan, Italy which demonstrate the significant potential of macrophage cell therapy as a treatment for advanced liver cirrhosis.

READ MORE +

CEO's Statement

Resolution is at the forefront of a new kind of cell therapy. We’re treating inflammatory organ disease with macrophages, the cells that the body uses to resolve injury and heal wounds. Our work builds on a huge body of science understanding the role of macrophages as orchestrators of the wound healing process; coupled with our world-leading founders, a top-quality scientific staff and proprietary insight into macrophage biology and manufacturing, we are poised to improve the lives of countless patients worldwide.

Amir Hefni CEO